Cargando…
Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342392/ https://www.ncbi.nlm.nih.gov/pubmed/37445309 http://dx.doi.org/10.3390/jcm12134274 |
_version_ | 1785072488150990848 |
---|---|
author | Khan, Zuber Gupta, Ghanshyam Das Mehan, Sidharth |
author_facet | Khan, Zuber Gupta, Ghanshyam Das Mehan, Sidharth |
author_sort | Khan, Zuber |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India’s treatment techniques vary. In addition, India’s population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition. |
format | Online Article Text |
id | pubmed-10342392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103423922023-07-14 Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges Khan, Zuber Gupta, Ghanshyam Das Mehan, Sidharth J Clin Med Review Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India’s treatment techniques vary. In addition, India’s population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition. MDPI 2023-06-26 /pmc/articles/PMC10342392/ /pubmed/37445309 http://dx.doi.org/10.3390/jcm12134274 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Khan, Zuber Gupta, Ghanshyam Das Mehan, Sidharth Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges |
title | Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges |
title_full | Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges |
title_fullStr | Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges |
title_full_unstemmed | Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges |
title_short | Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges |
title_sort | cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342392/ https://www.ncbi.nlm.nih.gov/pubmed/37445309 http://dx.doi.org/10.3390/jcm12134274 |
work_keys_str_mv | AT khanzuber cellularandmolecularevidenceofmultiplesclerosisdiagnosisandtreatmentchallenges AT guptaghanshyamdas cellularandmolecularevidenceofmultiplesclerosisdiagnosisandtreatmentchallenges AT mehansidharth cellularandmolecularevidenceofmultiplesclerosisdiagnosisandtreatmentchallenges |